Subscribe
nitpicker
nitpicker / shutterstock.com
5 May 2020Asia-Pacific

Setback for Gilead in GSK HIV antiviral suit

An Australian federal judge has thrown out a challenge by  Gilead Sciences to the wording of infringement claims made by a  GlaxoSmithKline (GSK) subsidiary.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks